Dec 12, 2024
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Dec 10, 2024
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
Nov 14, 2024
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
Nov 08, 2024
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Nov 06, 2024
Volition Appoints Timothy I. Still as Chairman
Oct 09, 2024
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
Oct 03, 2024
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
Sep 30, 2024
Volition Appoints Dr. Ethel Rubin as an Independent Director
Sep 11, 2024
Volition Hosts KOL Roundtable on Sepsis
Aug 09, 2024
VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
Aug 06, 2024
VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
Jul 09, 2024
Volition appoints PharmaVentures for Capture PCR(TM) and oncology portfolio licensing
May 29, 2024
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
Apr 23, 2024
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
Mar 25, 2024
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Mar 21, 2024
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Mar 20, 2024
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
Mar 19, 2024
Volition appoints Dr Andrew Retter as Chief Medical Officer
Jan 04, 2024
Volition Issues Business Review 2023
Feb 09, 2021
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock